Sladkova Vladimira, Mares Jan, Lubenova Blanka, Hlustik Petr, Kanovsky Petr
Department of Neurology, Palacky University Medical School, University Hospital, Olomouc, Czech Republic.
Neuro Endocrinol Lett. 2011;32(1):4-6.
Drug-induced systemic lupus erythematosus (SLE) is a rare complication of therapies with some drugs. Breaking out after months or years of therapy with a certain drug, its occurrence is likely to increase with the duration of the medication and the cumulative quantity of the drug. The symptoms of this syndrome include, in particular, arthralgia, myalgia, fever, serositis, skin exanthema and production of antinuclear (ANA) antibodies. In contrast to SLE, its symptoms gradually abate after discontinuation of the inducing agent. The authors describe the case of a 43-year-old patient suffering from multiple sclerosis who experienced drug-induced SLE after 8-year application of interferon (IFN) beta-1b.
药物性系统性红斑狼疮（SLE）是某些药物治疗罕见的并发症。在使用某种药物治疗数月或数年后发病，其发生率可能随用药时间和药物累积量增加而升高。该综合征的症状尤其包括关节痛、肌痛、发热、浆膜炎、皮肤疹和抗核（ANA）抗体产生。与系统性红斑狼疮不同，停用诱发药物后其症状会逐渐减轻。作者描述了一例43岁的多发性硬化症患者，在应用β-1b干扰素8年后发生了药物性系统性红斑狼疮。
